PARTNER CONTENT
Benefits
Jeff Boutilier
General Manager, Pharmacy, and Chief Clinical Officer, Express Scripts Canada
“More than 30 new rare disease treatments are on the horizon. That’s great from a treatment standpoint, but these treatments come with extremely high prices that will continue to put a lot of pressure on private drug plan spend.”
Angelo Tsebelis and Dr. Peter Blecher
Starseed Medicinal Inc.
“Our mandate is to differentiate ourselves by focusing on the safe and responsible use of cannabis in the workplace. We will strive to have medical cannabis become a paid benefit, so we can help break the devastating cycle of opiate use and abuse.”
Francesco Di Marco, PhD
Vice President and General Manager, Amgen Canada Inc.
“We understand the issues that are relevant to our private payers and their customers, including, but not limited to, cost. By recognizing how medicines impact working-age individuals and their families, we can support private payers in making informed, evidence-based decisions that are tailored and relevant to the specific needs of their customers.”
Atul Goela
Director, Pharmaceutical Benefits, Sun Life Financial
It is great to see advancement in medical sciences offering innovative drug treatment choices for diseases where there were no options in the past or new drug treatments that now are curative; however, from a drug plan management perspective, how do we manage the costs to ensure sustainability?”
Colleen Hutchings, MA, CDMP
Director, Organizational Health, Practice Excellence & Innovation Sun Life Financial
“Plan sponsors want a deeper partnership with their insurer and health providers. They want access to the expertise to help identify risks and develop strategies for improvement in their organization.”